Results 71 to 80 of about 53,217 (270)
Recommendations for Nomenclature in Cholinesterases
Information gathered on the genomic organization of cholinesterase genes, advances in biochemical characterization of the various subunits and the elucidation of the tertiary structure of the T.
Doctor, Bhupendra P. +9 more
core +1 more source
Cholinesterase inhibitors in advanced dementia with Lewy bodies: increase or stop?
, 2006 INTRODUCTION There is little data on stopping cholinesterase inhibitors in Dementia with Lewy bodies (DLB). Equally, it is not known if increasing the dose of cholinesterase inhibitors may help neuropsychiatric symptoms in advanced DLB.
Pakrasi, Sanjeet +7 more
core +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Parkinson's disease (PD) progression is highly heterogeneous, complicating clinical management and prognostication. While machine learning models have been developed using research datasets such as Parkinson's Precision Medicine Initiative (PPMI) and Parkinson's Disease Biomarkers Program (PDBP), their clinical translatability is ...
Xuehua Ye +9 more
wiley +1 more source
HETEROZYGOTES FOR ATYPICAL CHOLINESTERASE
British Journal of Anaesthesia, 1982 Three hundred and thirty-two patients undergoing electroconvulsive therapy received thiopentone and suxamethonium. In 31 the duration of the apnoea was greater than an assumed upper limit of normal of 240 s. Eight of these patients proved, on biochemical grounds, to be heterozygotes for the atypical gene. The reason why the heterozygous state is rarely
H, Owen, A R, Hunter
openaire +2 more sources
Rational Design of Cholinesterase Inhibitors
, 2000 With the collaboration of the most distinguished scholars in this field Professor Giacobini has put together a publication which will convey present knowledge in the field of molecular biology and genetics, biochemistry, cell biology, pharmacology and ...
FILOCAMO, Luigi, BRUFANI, Mario
core
Apathy in Lewy Body Disorders: A Position Paper
Movement Disorders, EarlyView.Abstract Apathy is one of the most prevalent and disabling non‐motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional outcomes, yet remains ...
Jaime Kulisevsky +12 more
wiley +1 more source
Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies
, 2004 This article reviews the cholinergic changes in Parkinson's disease and dementia (PDD) and dementia with Lewy bodies (DLB), their potential clinical implications, and the available evidence for cholinesterase inhibitors in the treatment of PDD and DLB ...
Aarsland, Dag +2 more
core +1 more source
Structure of human serum cholinesterase [PDF]
, 1988 Human cholinesterase has recently been sequenced and cloned. It is a glycoprotein of 4 identical subunits, each subunit containing 9 carbohydrate chains and 3.5 disulfide bonds.
Lockridge, Oksana
core +1 more source
Diagnosis of Portal Hypertension: Advancing Towards Non‐Invasive Solutions
Portal Hypertension &Cirrhosis, EarlyView.This review systematically summarizes a full spectrum of non‐invasive diagnostic approaches for portal hypertension (PH), including imaging modalities, elastography, serum biomarkers, composite scoring systems and endoscopic ultrasound‐guided portal pressure gradient (EUS‐PPG), and analyzes their performance across different liver disease etiologies ...
Lijia Yin, Huikuan Chu, Ling Yang
wiley +1 more source
Acute Toxicity and Neurobehavioral Effects of Diphenhydramine in Chicks
The Journal of Poultry Science, 2012 The present study was undertaken to examine the acute toxicity (LD50) and neurobehavioral manifestations in the open-field activity and tonic immobility tests in 7-14 day-old chicks treated with the H1-receptor antagonist diphenhydramine.
Fouad K. Mohammad +2 more
doaj +1 more source